Although the induction of tumor-specific cytotoxic CD8+ T cells by cross-presenting cDC1 is assumed pivotal for effective cancer immunity, a study by Neubert et al. showed that targeting of cDC2 was also protective and induced therapeutic immune responses in a model of murine melanoma [137]. This evidence concerns the gene CD8A and cancer.